Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Abrine (L). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 3/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | APAF1 | O14727 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ITGB2 | P05107 | 3/20 | 0.65 |
| ▸ | ICAM1 | P05362 | 3/20 | 0.65 |
| ▸ | ITGAL | P20701 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ECE1 | P42892 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MPO | P05164 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abrine SCHEMBL5056408 | 1.00 | ALOX15 (0.69) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine SCHEMBL23668057 | 1.00 | ALOX15 (0.69) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine SCHEMBL161767 | 0.99 | ALOX15 (0.70) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine SCHEMBL29404678 | 0.99 | ALOX15 (0.70) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine (L) SCHEMBL18777 | 0.99 | ALOX15 (0.70) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine (L) SCHEMBL29585648 | 0.99 | ALOX15 (0.70) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine SCHEMBL18778 | 0.99 | ALOX15 (0.70) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine SCHEMBL30320025 | 0.97 | ALOX15 (0.69) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine SCHEMBL8871893 | 0.97 | ALOX15 (0.69) | ALOX15ACEKDM4EMAPTAPAF1 | |
| Abrine SCHEMBL30413313 | 0.97 | ALOX15 (0.69) | ALOX15ACEKDM4EMAPTAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926466-A2 | STABLE EMULSION SYSTEMS WITH HIGH SALT TOLERANCE | COMBE INCORPORATED (US) | 2008-06-04 | — | — | EP | claimed |
| WO-2007040598-A2 | STABLE EMULSION SYSTEMS WITH HIGH SALT TOLERANCE | COMBE INCORPORATED (US) | 2007-04-12 | — | — | WO | claimed |
| US-20070065390-A1 | Stable emulsion systems with high salt tolerance | RECKITT BENCKISER LLC | 2007-03-22 | — | — | US | claimed |
| CN-112961096-B | Chalcone tryptophan derivatives with cisplatin nephrotoxicity and antitumor activity | 安徽医科大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-112961096-A | Chalcone tryptophan derivatives with improved cisplatin nephrotoxicity and antitumor activity | 安徽医科大学 | 2021-06-15 | — | — | CN | disclosed |
| CN-110156846-A | A kind of preparation process of D-galactosamine hydrochloride | 南京博源医药科技有限公司 | 2019-08-23 | — | — | CN | disclosed |
| EP-1926466-A2 | STABLE EMULSION SYSTEMS WITH HIGH SALT TOLERANCE | COMBE INCORPORATED (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007040598-A2 | STABLE EMULSION SYSTEMS WITH HIGH SALT TOLERANCE | COMBE INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070065390-A1 | Stable emulsion systems with high salt tolerance | RECKITT BENCKISER LLC | 2007-03-22 | — | — | US | disclosed |
| EP-0227787-B1 | PRODUCTION OF INDOLE ALPHA-KETOACIDS FROM ALPHA-AMINOACID, PARTICULARLY OF INDOLEPYRUVIC ACID | POLIFARMA S.p.A. (IT) | 1990-08-29 | — | — | EP | disclosed |
| EP-0227787-A1 | PRODUCTION OF INDOLE ALPHA-KETOACIDS FROM ALPHA-AMINOACID, PARTICULARLY OF INDOLEPYRUVIC ACID. | POLIFARMA SPA (IT) | 1987-07-08 | — | — | EP | disclosed |
| WO-1987000169-A1 | PRODUCTION OF INDOLE ALPHA-KETOACIDS FROM ALPHA-AMINOACID, PARTICULARLY OF INDOLEPYRUVIC ACID | POLIFARMA S.P.A. (IT) | 1987-01-15 | — | — | WO | disclosed |